Associations - AR mutation

AR mutation AR mutation	Prostate Cancer Prostate Cancer	AR mutation AR mutation	Prostate Cancer Prostate Cancer	PCM-075 Sensitive: C3 – Early Trials	PCM-075 Sensitive: C3 – Early Trials
AR mutation AR mutation	Prostate Cancer Prostate Cancer	AR mutation AR mutation	Prostate Cancer Prostate Cancer	abiraterone acetate + RG7440 Resistant: C3 – Early Trials	abiraterone acetate + RG7440 Resistant: C3 – Early Trials
AR mutation AR mutation	Prostate Cancer Prostate Cancer	AR mutation AR mutation	Prostate Cancer Prostate Cancer	enzalutamide capsule Resistant: C3 – Early Trials	enzalutamide capsule Resistant: C3 – Early Trials
AR mutation AR mutation	Prostate Cancer Prostate Cancer	AR mutation AR mutation	Prostate Cancer Prostate Cancer	abiraterone acetate Resistant: C3 – Early Trials	abiraterone acetate Resistant: C3 – Early Trials
AR mutation AR mutation	Prostate Cancer Prostate Cancer	AR mutation AR mutation	Prostate Cancer Prostate Cancer	ODM-208 Sensitive: C3 – Early Trials	ODM-208 Sensitive: C3 – Early Trials
AR mutation AR mutation	Prostate Cancer Prostate Cancer	AR mutation AR mutation	Prostate Cancer Prostate Cancer	CPI-0209 Sensitive: D – Preclinical	CPI-0209 Sensitive: D – Preclinical
AR mutation AR mutation	Prostate Cancer Prostate Cancer	AR mutation AR mutation	Prostate Cancer Prostate Cancer	docetaxel Resistant: D – Preclinical	docetaxel Resistant: D – Preclinical
AR mutation AR mutation	Prostate Cancer Prostate Cancer	AR mutation AR mutation	Prostate Cancer Prostate Cancer	5-fluorouracil Resistant: D – Preclinical	5-fluorouracil Resistant: D – Preclinical